Now showing items 1-1 of 1

    • Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two staged, adaptive placebo controlled trial (APRICOT) 

      Cro, S.; Cornelius, V. R.; Pink, A. E.; Wilson, R.; Pushpa-Rajah, A.; Patel, P.; Abdul-Wahab, A.; August, S.; Azad, J.; Becher, G.; Chapman, A.; Dunnil, G.; Ferguson, A. D.; Fogo, A.; Ghaffar, S. A.; Ingram, J. R.; Kavakleiva, S.; Ladoyanni, E.; Leman, J. A.; Macbeth, A. E.; Makrygeoegou, A.; Parslew, R.; Ryan, A. J.; Sharma, A.; Shipman, A. R.; Sinclair, C.; Wachsmuth, R.; Woolf, R. T.; Wright, A.; McAteer, H.; Barker, Jnwn; Burden, A. D.; Griffiths, C. E. M.; Reynolds, N. J.; Warren, R. B.; Lachmann, H. J.; Capon, F.; Smith, C. H. (Wiley, 2021-08-19)
      BACKGROUND: Palmoplantar pustulosis (PPP) is a rare, debilitating, chronic inflammatory skin disease affecting the hands and feet. Clinical, immunological and genetic findings suggest a pathogenic role for interleukin ...